Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 4/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.46 |
| ▸ | NPY1R | P25929 | 3/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.42 |
| ▸ | TYMS | P04818 | 2/20 | 0.42 |
| ▸ | GART | P22102 | 2/20 | 0.42 |
| ▸ | ATIC | P31939 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16359252 | 0.88 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RTLR2 | |
| SCHEMBL7351702 | 0.86 | PLA2G10 (0.43) | NPY4RNPY5RNPY1RNPY2REPHX2 | |
| SCHEMBL13908025 | 0.85 | NOD1 (0.49) | FOLH1PLA2G10NOD1PLA2G2C | |
| SCHEMBL19724151 | 0.85 | NOD1 (0.49) | FOLH1PLA2G10NOD1PLA2G2C | |
| SCHEMBL13907995 | 0.84 | NPY4R (0.55) | NPY4RNPY5RNPY1RNPY2RFOLH1 | |
| SCHEMBL3651453 | 0.84 | NOD1 (0.55) | NPY4RNPY5RNPY1RNPY2REPHX2 | |
| SCHEMBL17304345 | 0.83 | NOD1 (0.52) | NPY4RNPY5RNPY1RNPY2REPHX2 | |
| SCHEMBL17304347 | 0.83 | NOD1 (0.52) | NPY4RNPY5RNPY1RNPY2REPHX2 | |
| SCHEMBL17304354 | 0.83 | NOD1 (0.52) | NPY4RNPY5RNPY1RNPY2REPHX2 | |
| SCHEMBL17304349 | 0.83 | NOD1 (0.52) | NPY4RNPY5RNPY1RNPY2REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200215199-A1 | COMPOUNDS FOR TREATING CANCER | BICYCLETX LIMITED (GB) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200215199-A1 | COMPOUNDS FOR TREATING CANCER | TP53, VHL, MYC | NPY4R 4724/4885NPY5R 4575/4885NPY1R 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.